Eyevance Pharmaceuticals acquires FreshKote

Eyevance Pharmaceuticals announced that it acquired the FreshKote line of lubricant eyedrops from Focus Laboratories.

FreshKote products consist of a variety of formulations Eyevance said in a press release, which includes a preservative-free (PF) product that treats dry eye, supporting the three layers of the eye’s tear film and mimicking its lipid layer.

“The acquisition of the FreshKote franchise represents an important business milestone for Eyevance, which is actively building a portfolio of impactful and innovative eye care products focused on the anterior segment of the eye,” Jerry St. Peter, CEO and director of Eyevance, said in the release. “With the introduction of FreshKote PF, Eyevance is the first and only company to now offer an eye lubricant product line that is exclusively preservative free, available in both multidose bottle and single-unit vials.”

In addition to the acquisition of FreshKote, Eyevance has also recently announced a licensing agreement with Nicox Ophthalmics Inc. for Zerviate 0.24%, a prescription-only agent used to treat ocular itching due to allergic conjunctivitis, according to the release. Zerviate is set to launch in early 2019.

 

 

 

 

Eyevance Pharmaceuticals announced that it acquired the FreshKote line of lubricant eyedrops from Focus Laboratories.

FreshKote products consist of a variety of formulations Eyevance said in a press release, which includes a preservative-free (PF) product that treats dry eye, supporting the three layers of the eye’s tear film and mimicking its lipid layer.

“The acquisition of the FreshKote franchise represents an important business milestone for Eyevance, which is actively building a portfolio of impactful and innovative eye care products focused on the anterior segment of the eye,” Jerry St. Peter, CEO and director of Eyevance, said in the release. “With the introduction of FreshKote PF, Eyevance is the first and only company to now offer an eye lubricant product line that is exclusively preservative free, available in both multidose bottle and single-unit vials.”

In addition to the acquisition of FreshKote, Eyevance has also recently announced a licensing agreement with Nicox Ophthalmics Inc. for Zerviate 0.24%, a prescription-only agent used to treat ocular itching due to allergic conjunctivitis, according to the release. Zerviate is set to launch in early 2019.